In addition to three vaccines against Covid-19 approved and produced in the country, Cuban scientists are advancing in other treatments for various diseases and one of them is NeuralCIM, which achieves positive results in patients with Alzheimer’s, Parkinson’s and Ataxia.
“What it does is to prolong a little more the life of the nervous system cells, so that the symptoms are more spaced out and the disease does not progress so quickly,” neurologist Héctor Vera said.
Vera believes that the results are extraordinary and if they are confirmed in the next phases, their contribution to the care of patients with Alzheimer’s disease and other forms of dementia worldwide would be enormous.
Dr. Leslie Pérez, from the Center for Molecular Immunology (CIM), one of the institutions involved in the research and development of NeuralCIM, explained that the third phase of the trial would take place in Havana and the fourth phase would cover the whole country.
A total of 413 people will be involved in the initial phase and 1,456 will participate once it expands to other locations, Pérez told Radio Habana Cuba.
Additional diagnostic procedures will be carried out to confirm that patients suffer from Alzheimer’s and not another form of dementia, and in case there is another disease, patients will be referred to specialists for appropriate forms of care.
The effects of NeuralCIM will be compared with those of Donepezil, a dementia drug approved for use in the United States.